Introducing LymphDetect™ Head & Neck

CLIA test identifies head and neck cancer recurrence with unprecedented immediacy and sensitivity

Post-surgical lymphatic fluid contains unique and vital markers to guide treatment decisions.

LymphDetect™ Head & Neck, measures circulating tumor DNA (ctDNA) in surgical drain fluid, the most proximal biofluid to a recently resected tumor, to assess cancer recurrence risk at the source of potential spread – before it can travel to other parts of the body.

LymphDetect™ Head & Neck offers clinicians and their patients the ability to:

Post surgery, ctDNA is >100X more concentrated in the lymphatic fluid at the tumor resection site versus a blood draw. LymphDetect takes advantage of this enhanced biological sensitivity.

Sample collection at the earliest time post-surgery to inform and confirm treatment decisions, and fits within clinician workflows.

Complements existing molecular residual disease (MRD) solutions that monitor recurrence risk weeks or months later.

Distinguished otolaryngology medical centers across North America are collaborating with Droplet on LymphDetect™ Head & Neck.

For information on our Early Access Program, please complete this form: